Psonet

Drugs in development

New therapies in development for psoriasis: what changes in clinical research?

Biological drugs have been considered a scientific and clinical progress in the treatment of psoriasis. However, their role can be fully assessed only when randomized controlled trials will compare them with each other and with conventional drugs, and when data efficacy and safety in the long term will become available  

Meanwhile, search for new molecules carries on and in the near future new therapies will become available: some of these drugs are already used in clinical Phase II and III, while others are in early stages of development.

For drugs close to market, it seems desirable to rely on post-marketing evaluation systems: studies of efficacy and long-term safety, comparison and for assessing outcomes (end point) clinically relevant outcomes, not surrogates.

Here you can find an overview of the state of the art of these new molecules. Information on clinical trials in progress will be regularly updated.

Mechanism Compound Administration route Phase Sponsor

TNF alfa inhibitor

Certolizumab pegol (Cimzia) Subcutaneous

III

UCB
CF101 Oral

II/III

Can-Fite BioPharma

Cytokine inhibitor -

phosphodiesterase 4 inhibitor

CC 10004 (Apremilast) Oral

IV

FDA approval

Celgene Corporation

 

IL-12/23 inhibitor CNTO 1275 (Ustekinumab)

Intravenous,

subcutaneous

III

FDA approval

Centocor  Medarex
IL-15 inhibitor AMG 714 Subcutaneous

II

Amgen
Calcineurin inhibitor ISA 247 (Voclosporin) Oral

III

Aurinia Pharmaceuticals Inc.

Retinoic acid regulator

R115866

(Rambazole)

 

Oral, topical

II

Stiefel

PNP (purine nucleotide phosphorilase) inhibitor R3421 / BCX-4208 Oral

II

Hoffmann-La Roche
Anti-inflammatory

ILV-094

(Fezakinumab)

Subcutaneous, intravenous

I

Wyeth
T cell regulator Abatacept / BMS188667 (Orencia) Intravenous

II

Bristol-Meyer Squibb

Cytokine inhibitor

CP-690,550

(Tofacitinib)

Oral

III

Pfizer
Vitamin D2 Doxercalciferol (Hectorol) Oral

II

Genzyme
IL-17 inhibitor

AIN457

(Secukinumab)

Intravenous,

subcutaneous

II

Novartis

Immune regulator

PKC inhibitor

AEB071 Oral

II

Novartis
T cell regulator AbGn-168 Intravenous

I

Boehringer Ingelheim Pharmaceuticals
IL-17 inhibitor AMG 827

Subcutaneous

II

Valeant Pharmaceuticals International, Inc.
Immune regulator CNTO1959 Intravenous, subcutaneous

I

Centocor
Anti-inflammatory VB-201 Oral II Vascular Biogenics
Immune regulator BT061

Intravenous,

subcutaneous

II Biotest
IL-23 inhibitor SCH900222 Subcutaneous II Merck Sharp & Dohme Corp.

New molecule

 

RO5310074 Intravenous I Hoffmann-La Roche
IL-23 inhibitor LY2439821 Subcutaneous III Eli Lilly and Company
Anti-inflammatory SRT2104 Oral II Sirtris, a GSK Company
New molecule Apo805K1 Oral II ApoPharma
IL-27 inhibitor KHK4827

Subcutaneous

Intravenous

I Kyowa Hakko Kirin Company, Limited
JAK1-JAK2 inhibitor LY3009104 Oral II Eli Lilly and Company
INFgamma, TNF-alfa inhibitor LEO 32731 Oral II LEO Pharma

Read more

You can find more information about ongoing clinical trials and drugs in development at the following addresses:

http://www.clinicaltrials.gov/

http://www.psoriasis.org/research/pipeline/chart.php

http://controlled-trials.com/ 

http://www.who.int/ictrp/en/

http://www.anzctr.org.au/default.aspx